TrialClinical pharmacology in drug development2026

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of Firsekibart in Chinese Healthy Participants.

Xiaolan Yong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.